Free Confidential Lawsuit Review
If you or another loved one was injured by Lipodrene side effects, you should contact our law firm immediately. You may be entitled to compensation by filing a Lipodrene Class Action Lawsuit and our lawyers can help. Please click the button below for a Free Confidential Case Evaluation or call us toll-free 24 hrs/day by dialing (866) 223-3784.

Start My Free Case Review

What’s the Problem?

This FDA Recall began on May 12, 2021, and affects Lot # 001211197, Exp. 12/25 of Lipodrene w/25mg Ephedra Extract Dietary Supplement.

Hi-Tech Pharmaceuticals. Inc. initiated this recall after an FDA analysis found the presence of DMAA in the recalled Lipodrene. Affected supplements were purchased by and distributed through wholesale and direct sales in the U.S. and Puerto Rico, and through online sales for both personal use and retail sales.

“The FDA has warned that DMAA is dangerous because it can narrow blood vessels and arteries and cause a corresponding rise in blood pressure or other cardiovascular problems, such as: Shortness of breath, Arrhythmias, Elevated blood pressure, Tightening in the chest, and Heart attack,” the agency said.

Consumers who purchased any recalled dietary supplements should either discard them or return them for a refund.

Do I Have a Lipodrene Class Action Lawsuit?

The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Lipodrene Lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.

If you or another loved one was harmed by the side effects of Lipodrene, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

FREE Confidential Case Evaluation

To contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 223-3784.

  • This field is for validation purposes and should be left unchanged.